Back to Authors

Andersen, Marianne

https://orcid.org/0000-0002-4603-9504

Mayo Clinic

Odense University Hospital

Citations 2

Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study
Yu, Kai , Ebbehøj, Andreas , Obeid, Hiba, Vaidya, Anand , Else, Tobias , Wachtel, Heather , Main, Ailsa Maria , Søndergaard, Esben , Christensen, Louise Lehmann , Cohen, Debbie L. , Bennett, Bonita, Andersen, Marianne , Larsson, Catharina , Almeida, Madson Q. , Boorjian, Stephen A. , Ebbehøj, Andreas Ladefoged , Fishbein, Lauren , Bancos, Irina , Almeida, Madson Q , Juhlin, C. Christofer , Calissendorff, Jan , Young, William F. , Bancos, Irina

The Journal of Clinical Endocrinology & Metabolism | July 26, 2022 | Volume: 107 | Issue: 10 | Pages: 2811-2821

10.1210/clinem/dgac427 Get It

Abstract Context Urinary bladder paraganglioma (UBPGL) is rare. Objective We aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL. Methods We conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality. Results Patients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality. Conclusions Only a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.
Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome
Glintborg, Dorte , Støving, René Klinkby , Hagen, Claus, Hermann, Anne Pernille , Frystyk, Jan , Veldhuis, Johannes D. , Flyvbjerg, Allan , Andersen, Marianne

The Journal of Clinical Endocrinology & Metabolism | October 5, 2005 | Volume: 90 | Issue: 10 | Pages: 5605-5612

10.1210/jc.2005-0615 Get It